Roche Holding AG
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2011-05-10
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 485
- Registration Number
- NCT01351415
- Locations
- πΊπΈ
University of Pennsylvania; Radiation Oncology, Philadelphia, Pennsylvania, United States
π―π΅Miyagi Cancer Center; Respiratory Medicine, Miyagi, Japan
πΊπΈUSA Mitchell Cancer Institute, Mobile, Alabama, United States
A Study on the Effect of Food on the Pharmacokinetics of RO5428029 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: RO5428029
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT01345942
A Study of Administration of Trastuzumab (Herceptin) by a Single-use Injection Device Versus a Handheld Syringe
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 119
- Registration Number
- NCT01344863
An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)
Completed
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4459
- Registration Number
- NCT01344889
An Observational Study on Bevacizumab (Avastin) as First-Line Treatment in Colorectal Cancer Participants With Potentially Resectable Liver Metastases
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 210
- Registration Number
- NCT01343901
- Locations
- π«π·
Fondation Bergonie; Gastro-Enterologie, Bordeaux, France
π«π·Clinique De L Europe; Pmsi, Amiens, France
π«π·Clinique Esquirol Saint Hilaire, Agen, France
An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)-Based First-Line Therapy
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 118
- Registration Number
- NCT01343914
A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia
Phase 4
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2011-04-27
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 70
- Registration Number
- NCT01342640
- Locations
- πͺπ¬
Kasr El Ainy University Hospital; Endocrinology Department, Cairo, Egypt
πͺπ¬Nasser Institute, Cairo, Egypt
πͺπ¬Alexandria University; Endocrinology Department, Alexandria, Egypt
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
- First Posted Date
- 2011-04-27
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 217
- Registration Number
- NCT01342965
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Completed
- Conditions
- Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2011-04-22
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 314
- Registration Number
- NCT01340443
- Locations
- π¨π³
Xiangya Hospital of Centre-South University, Changsha, China
π¨π³Lanzhou General Hospital, PLA Lanzhou Military Area Command, Lanzhou, China
π¨π³the First Hospital of Jilin University, Changchun, China
An Observational Study of Xeloda (Capecitabine) and Oxaliplatin Prior and Concurrent To Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2011-04-21
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT01339832
Β© Copyright 2025. All Rights Reserved by MedPath